The fixed-dose combination of tiotropium + olodaterol has a rapid onset of action in patients with COPD

Author(s):  
Gary T. Ferguson ◽  
Emilio Pizzichini ◽  
Matjaz Flezar ◽  
Lars Grönke ◽  
Lawrence Korducki
Pneumologie ◽  
2016 ◽  
Vol 70 (S 01) ◽  
Author(s):  
C Priegnitz ◽  
GT Ferguson ◽  
E Pizzichini ◽  
M Flezar ◽  
L Grönke ◽  
...  

2013 ◽  
Vol 10 (4) ◽  
pp. 60-64
Author(s):  
A V Emelyanov

The review focused on mometasone furoate/formoterol (MF/F), a new fixed dose combination (Zenhale, MDI 50/5, 100/5 and 200/5 mcg/dose) for treatment of asthma in adults and children 12 years of age and older. New combination should be used for patients not adequately controlled with inhaled corticosteroids (ICS) and «as needed» inhaled short acting β 2-agonist or those whose disease severity warrants initiation of treatment with two maintenance therapies. It may be also used in patients already adequately controlled on both ICS and long-acting β 2-agonist. Data from randomized placebo controlled clinical trials confirm that MF/F has fast onset of action, reduces number of exacerbations, improves lung function, quality of life and asthma control. MF/F has a good safety profile.


Author(s):  
Bobde Suwarna Suresh ◽  
Tank Hemraj M

Objective: The present research aims at formulating a mouth dissolving sublingual film of fixed dose combination of doxylamine succinate (DS) and pyridoxine hydrochloride (PH) that would provide faster onset of action and hence relief from the condition of nausea and vomiting in pregnancy.Methods: Mouth dissolving films were prepared using a solvent casting technique. A 23 full-factorial design of eight formulations was set up with three independent variables: X1 - polymer 1 HPMC E15 concentration, X2 - polymer 2 HPMC E5 concentration, and X3 - plasticizer PEG 400 concentration. The responses, i.e., dependent variables measured for the study were Y1 disintegration time in seconds, Y2 tensile strength in kg/cm2, Y3 drug release in the percentage of DS, and Y4 drug release in the percentage of PH. All the formulations were evaluated for physicochemical parameters such as clarity, weight, thickness, folding endurance, surface pH, and content. The design expert software 11.0 trial version was used for statistical analysis of the responses.Results and Conclusion: All the film formulations were found to be transparent, non-tacky, and easily peelable having the satisfactory tensile strength and folding endurance. The concentration of polymer 1 and 2 was found to have a significant effect on disintegration time and drug release of mouth dissolving films. The best film formulation DP1 was found to have a disintegration time of 77.66 s and found to release 96.22% of DS and 95.43% of pyridoxine HCl in 21 min.


2010 ◽  
Vol 2 ◽  
pp. 1179559X1000200
Author(s):  
Mohammad Hamzavi

Inhaled corticosteroids are the mainstay of asthma therapy, but there is now compelling evidence that addition of a long-acting inhaled β2-agonist, such as formoterol, gives better control in terms of reduced symptoms, improved lung function and reduced exacerbations in patients with mild to severe persistent asthma than increasing the dose of corticosteroids in patients not fully in control by low dose. This has led to development of fixed dose combination inhalers such as budesonide/formoterol. Budesonide/formoterol combination in a single inhaler represents a safe, effective and convenient treatment option for management of patients with unstable asthma than inhaled steroid alone. This combination has shown effectiveness for both maintenance and rescue therapy. Clinical results show that the budesonide/formoterol by SMART approach prolongs the time to first severe asthma exacerbation, reduces frequency of exacerbation and maintains day to day asthma control at a reduced corticosteroid load and cost when compared with higher fixed maintenance dose of combination inhalers. With regular maintenance therapy by this approach it is more likely to improve patient compliance. Budesonide/formoterol combination inhaler has shown to have a faster bronchodialatory effect compared with other combination inhalers, a quality highly in demand during exacerbation episodes. Due to this rapid onset of action, budsonide/formoterol in a single inhaler lends itself to be used as a rescue medication, as well.


Pneumologie ◽  
2016 ◽  
Vol 70 (S 01) ◽  
Author(s):  
ED Bateman ◽  
K Chapman ◽  
S Rennard ◽  
L Rekeda ◽  
M Moya ◽  
...  

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 135-OR
Author(s):  
ELENI PAPPA ◽  
CHRISTINA KOSTARA ◽  
CONSTANTINOS TELLIS ◽  
ALEXANDROS D. TSELEPIS ◽  
ELENI BAIRAKTARI ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document